HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Hoeper, M.M. Search for Related Content PubMed PubMed Citation Articles by Hoeper, M.M.

Pulmonary hypertension in collagen vascular disease

Hannover Medical School, Dept of Pulmonary Medicine, Hannover, Germany

CORRESPONDENCE: M.M. Hoeper, Hannover Medical School, Dept of Pulmonary Medicine, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Fax: 49 5115328536. E-mail: hoeper.marius@mh-hannover.de

Keywords: calcinosis, Raynauds phenomenon, oesophageal involvement, sclerodactyly, and teangiectasia (CREST) syndrome, prostacyclin, pulmonary hypertension, scleroderma, secondary, systemic sclerosis

Received: September 16, 2001
Accepted September 17, 2001

Abstract

Pulmonary hypertension is a serious but often overlooked complication in collagen vascular disease. The understanding of the development of pulmonary hypertension has increased substantially during the last years.

Abnormal proliferation of pulmonary vascular cells is now being regarded as a predominant process leading to pulmonary vascular obliteration. Medical therapy focuses on prostacyclin treatment, which has been shown to improve exercise capacity and haemodynamic variables in patients with several collagen vascular diseases and pulmonary arterial hypertension.

Continuous intravenous prostacyclin remains the standard treatment of associated pulmonary hypertension but less invasive alternatives such as subcutaneous treprostinil, oral beraprost or aerosolized iloprost, as well as, novel substances such as endothelin receptor antagonists may be appropriate for selected patients.

This article has been cited by other articles:

				L. Taraseviciene-Stewart, M. R. Nicolls, D. Kraskauskas, R. Scerbavicius, N. Burns, C. Cool, K. Wood, J. E. Parr, S. A. Boackle, and N. F. Voelkel Absence of T Cells Confers Increased Pulmonary Arterial Hypertension and Vascular Remodeling Am. J. Respir. Crit. Care Med., June 15, 2007; 175(12): 1280 - 1289. [Abstract] [Full Text] [PDF]

				L. Mouthon, L. Guillevin, and M. Humbert Pulmonary arterial hypertension: an autoimmune disease? Eur. Respir. J., December 1, 2005; 26(6): 986 - 988. [Full Text] [PDF]

				E Hachulla and J G Coghlan A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism Ann Rheum Dis, September 1, 2004; 63(9): 1009 - 1014. [Abstract] [Full Text] [PDF]